Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

MRD-driven strategies and novel immunotherapies for multiple myeloma

Share :

Myeloma Knowledge Exchange 2021 (MyKE Myeloma)

18 Oct 2021
Published: 25 Oct 2021
Views: 1144
Rating:
Save
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Simon Harrison speaks to ecancer about MRD-driven strategies and novel immunotherapies for multiple myeloma.

He talks about his presentation at MyKE Myeloma 2021.

Initially, Prof Harrison talks about the MRD-driven strategies in NDMM.

He then explains some of the novel immunotherapies for multiple myelomas.

Prof Harrison concludes by discussing bispecific antibodies, CAR T therapies and ADCs.

 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
Dr Stephen Chun - MD Anderson, Houston, USA
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )
14 Sep 2023
OncoAlert Round Up for August 25th - 31st, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Sep 2023
Latest in immunological technologies that can treat, control, and prevent cancer
Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute
Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )
16 Aug 2023
NSIA and Nigeria to improve treatment for Nigerians through the building of new...
Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA)
NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres ( Aminu Umar-Sadiq - MD & CEO, Nigeria Sovereign Investment Authority (NSIA) )
26 May 2023
Choosing Wisely in pathology
Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
18 May 2023
Choosing Wisely in radiology Tanzania
Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
18 May 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )
2 May 2023
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
22 Mar 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation